Global Fintech Leaders Join Forces Behind Pollinate Platform
31.10.2019 14:17:00 EET | Business Wire | Press release
Pollinate, the business behind Tyl by NatWest, has launched with a growth capital investment round from a consortium of global industry leaders. Mastercard, Motive Partners and EFM Asset Management (EFM) will join RBS as both investors in, and partners to, the Pollinate business, which has raised a total of £60 million in funding to date.
Over the past decade, disruptive payment companies have challenged retail banks for ownership of their merchant relationships. Pollinate is reinventing merchant acquiring for banks, enabling them to compete effectively with these disruptors. The Pollinate technology is an innovative cloud-based platform that wraps around a bank’s legacy payment systems. The platform powers merchant and consumer digital experiences including onboarding, portals and loyalty programs, without costly and distracting platform migrations. This allows merchants to more effectively manage their businesses with digital tools and data integrations, grow their businesses by connecting with their consumers, and give back to their local communities. For banks, the Pollinate platform helps them understand and engage with their customers better and build stronger relationships with their merchants and consumers alike.
Conceived in 2017, the first deployment of the platform took place in Spring 2019 with the launch of the Tyl by NatWest merchant services business in the UK, and Pollinate is now in advanced discussions with other leading retail banks around the world.
Commenting on the announcement Alison Rose, Deputy CEO of NatWest Holdings and CEO of Commercial & Private Banking at RBS said, “I am hugely excited to announce the creation of a global merchant services company with Mastercard, Motive Partners and EFM Asset Management. Partnering with such high-quality companies, each of us bringing unique expertise and skills, allows for a truly international offering, benefitting not only our customers but the wider merchant acquiring space. We are committed to continually improving the products and experiences that we deliver to our customers, and the creation of Pollinate represents an innovative and successful approach of working with partners to do this.”
Jeff Emmanuel, Chief Investment Officer and Founder of EFM added: “As technology companies around the world are reimagining the delivery of financial services, a number of fintech ‘enablers’ have recognised the opportunity in bridging technological innovation, and the distribution scale and brand value of the largest financial institutions. Our disruptive fintech fund seeks opportunities through investment in dynamic companies which leverage their capabilities to deliver improved customer outcomes. Through combining machine learning with a unique ecosystem of data assets, Pollinate offers banks an exciting new service proposition for their customers. We are delighted to be backing this great team, and through our board participation, look forward to leveraging our network and experience in the space to maximise the opportunity.”
Pollinate is run by a team of executives from the Payments, Technology and Loyalty industries including Al Lukies CBE, Jonathan Hughes, Fiona Roach Canning, Tim Joslyn, David Beresford and Anna Moore.
Al Lukies, Pollinate CEO and Co-Founder said: “Retail banks around the world are facing common issues, but they remain the only ones in the payment chain who can connect directly with both merchants and consumers. They are therefore best placed to help SME’s process transactions, support their balance sheets, and grow their businesses, creating a virtuous circle between the bank, merchants, and consumers. As we know consumers increasingly expect a more personalised service from the businesses they interact with, regardless of their size, so at its heart Pollinate is about relationships and growth through connection - our platform enables relationships to be strengthened through fantastic digital experiences, and real-time data processing analytics and integrations.”
"Technology is making our everyday easier and more accessible. For small business owners, it's critical to separate the potential from the performance. That's why we're involved with Pollinate" said Ajay Banga, President and CEO of Mastercard. "Each of the partners brings its know-how, insights and technology to provide banks with real, tangible solutions that enables business owners to deliver the best customer experience."
Pollinate has secured important alliances with best in class brands across the payments and technology ecosystem. Available globally through the Azure cloud, the Pollinate platform utilises the best of Microsoft's big data and distributed AI platforms, threat Intelligence and authentication services to give banks and their customers access to compelling, intuitive services wherever they are. Other global partners of Pollinate, which include Mastercard, Endava, Motive Partners and EFM, ensures that Pollinate's banking clients, wherever they are based, can compete directly with the world's most innovative and disruptive companies.
“Our partner, Royal Bank of Scotland, has unique experience within the Merchant Services space and is perfectly positioned to roll out the Pollinate platform to small business across the United Kingdom. We are delighted to have a role alongside such an esteemed investor group, and we look forward to working with the Pollinate management team and our international ecosystem to building value for our partners, and ultimately SMEs and consumers.” - Rob Heyvaert, Managing Partner at Motive Partners.
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005483/en/
Contact information
Media contacts
Nicky Harrison
FieldHouse Associates
pollinate@fieldhouseassociates.com
07739338842
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 10:00:00 EEST | Press release
Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use cases demonstrating how AI and advanced automation are helping operators address increasing network complexity, strengthen fraud prevention, improve service assurance, and drive operational efficiency. A central theme across
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
